These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 31335805)

  • 1. A 24-week pilot study of dual maintenance therapy with raltegravir and lamivudine.
    de Lazzari E; Lonca M; Rojas J; Gonzalez-Cordon A; Blanch J; Inciarte A; Tricas A; Rodriguez A; Martinez-Rebollar M; Laguno M; Mallolas J; Sanchez-Palomino S; Plana M; Blanco JL; Martinez E
    AIDS; 2019 Oct; 33(12):1891-1896. PubMed ID: 31335805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
    Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L;
    J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection.
    Casado JL; Bañón S
    Expert Rev Clin Pharmacol; 2015; 8(6):709-18. PubMed ID: 26517111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
    Fabbiani M; Mondi A; Colafigli M; D'Ettorre G; Paoletti F; D'Avino A; Ciccarelli N; Sidella L; Murri R; Fortuna S; Vullo V; Cauda R; De Luca A; Di Giambenedetto S
    Scand J Infect Dis; 2014 Jan; 46(1):34-45. PubMed ID: 24161018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raltegravir/nevirapine dual therapy at reduced doses as 'maintenance' treatment in virally suppressed HIV-infected patients.
    Lanzafame M; Lattuada E; Rigo F; Nicole S; Cucchetto G; Vento S
    AIDS; 2015 Aug; 29(13):1722-3. PubMed ID: 26372286
    [No Abstract]   [Full Text] [Related]  

  • 6. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.
    Mondi A; Fabbiani M; Ciccarelli N; Colafigli M; D'Avino A; Borghetti A; Gagliardini R; Cauda R; De Luca A; Di Giambenedetto S
    J Antimicrob Chemother; 2015; 70(6):1843-9. PubMed ID: 25885326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Raltegravir-Etravirine Combination as Maintenance Regimen in Virologically Suppressed HIV-1-Infected Patients.
    Calza L; Magistrelli E; Colangeli V; Manfredi R; Borderi M; Rossi N; Conti M; Mancini R; Viale P
    AIDS Res Hum Retroviruses; 2017 Jul; 33(7):632-638. PubMed ID: 28088884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).
    Mussini C; Roncaglia E; Borghi V; Rusconi S; Nozza S; Cattelan AM; Segala D; Bonfanti P; Di Biagio A; Barchi E; Focà E; Degli Antoni A; Bonora S; Francisci D; Limonta S; Antinori A; D'Ettorre G; Maggiolo F
    PLoS One; 2019; 14(9):e0222650. PubMed ID: 31560700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen.
    Rizzardini G; Gori A; Miralles C; Olalla J; Molina JM; Raffi F; Kumar P; Antinori A; Ramgopal M; Stellbrink HJ; Das M; Chu H; Ram R; Garner W; Shao Y; Chuck SK; Piontkowsky D; Haubrich RH
    AIDS; 2019 Aug; 33(10):1583-1593. PubMed ID: 31305329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.
    Troya J; Montejano R; Ryan P; Gómez C; Matarranz M; Cabello A; Vera F; Sepúlveda MA; Santos I; Samperiz G; Bachiller P; Boix V; Barrufet P; Cervero M; Sanz J; Solís J; Yllescas M; Valencia E;
    PLoS One; 2018; 13(6):e0198768. PubMed ID: 29902204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
    HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience of raltegravir with abacavir/lamivudine or zidovudine/lamivudine in HIV-infected Korean adults.
    Kang SJ; An JH; Kim J; Jang MO; Kim SE; Park KH; Jung SI; Jang HC
    Jpn J Infect Dis; 2013; 66(4):317-9. PubMed ID: 23883843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting.
    Marinaro L; Calcagno A; Ripamonti D; Cenderello G; Pirriatore V; Trentini L; Salassa B; Bramato C; Orofino G; D'Avolio A; Rizzi M; Di Perri G; Rusconi S; Bonora S
    J Clin Virol; 2017 Feb; 87():30-36. PubMed ID: 27992788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics.
    Calcagno A; Montrucchio C; Capetti A; Guaraldi G; Cenderello G; Calza L; Lanzafame M; Marinaro L; Tettoni MC; Trentini L; D'Avolio A; Di Perri G; Bonora S
    Curr HIV Res; 2016; 14(1):54-60. PubMed ID: 26415700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
    Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
    Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial.
    Young B; Vanig T; Dejesus E; Hawkins T; St Clair M; Yau L; Ha B; Shield Study Team
    HIV Clin Trials; 2010; 11(5):260-9. PubMed ID: 21126956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
    Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
    Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.